bioAffinity's CyPath Lung test helps avoid biopsy in elderly patient case
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St set to open higher as chip stocks extend recovery; earnings in focus
- Oil prices rise over 2% on fresh attacks by US and Iran
- Chip stocks extend global rebound following last week's rout
- Citi's Chew says U.S. stock positioning unwind may not be over
- Adobe, Salesforce and Intuit fall as Morgan Stanley begins cautious coverage
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer
February 19, 2026 11:00 AM ESTCyPath® Lung test supported recommendation for surveillance strategy, rather than subjecting elderly patient to an invasive, risky and costly biopsy procedure
Despite a suspicious nodule during a low-dose CT scan, a repeat scan showed no nodules in the lungs, validating the decision made with CyPath® Lungs results
Noninvasive CyPath® Lung test has shown 92% sensitivity, 87% specificity and 88% accuracy for detecting lung cancer in small nodules less than 2 centimeters
SAN ANTONIO, Texas--(BUSINESS... More
